title: Effect of antiplatelet therapy for endovascular coiling in aneurysmal subarachnoid hemorrhage.
abstract: OBJECTIVE
  Antiplatelets are frequently used during or after endovascular coiling of aneurysm in patients with subarachnoid hemorrhage (SAH). This strategy is based on uncontrolled case series including also patients with unruptured aneurysms or other lesions. We collected data on effectiveness of antiplatelets in patients with SAH.
  
  
  METHODS
  All 43 participating centers in the International Subarachnoid Aneurysm Trial (ISAT) were sent a questionnaire whether they never, sometimes, or always prescribed antiplatelets during or after coiling. Based on individual patient data, the relative risks (RRs) of coiling versus clipping were calculated separately for patients treated in hospitals with standard prescription during or after coiling versus patients treated in hospitals with no standard prescription of antiplatelets. We calculated ratios of RRs for standard versus not standard prescription of antiplatelets during coiling and for standard versus not standard prescription after coiling.
  
  
  RESULTS
  Nineteen centers responded, representing 1422 (66%) of the 2143 ISAT patients. Antiplatelets were standard prescribed during coiling in 2 responding centers (8% of coiled patients) and after coiling in 6 centers (24%). For poor outcome at 2 months of coiling versus clipping the RR was 0.82 (95% CI: 0.45 to 1.49) in hospitals with a policy of antiplatelet prescription during coiling versus 0.66 (95% CI: 0.55 to 0.78) in those without such policy (ratio of RR's 1.24, P=0.56). The ratio of RRs for 1-year outcome was 1.01 (P=0.89) for antiplatelet use during coiling and 1.00 (P=0.77) for use after coiling.
  
  
  CONCLUSIONS
  The results of this study do not support the assumption that antiplatelets during or after endovascular coiling improve outcome in patients with SAH.
authors.affiliation: Department of Intensive Care, University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. w.m.vandenbergh@umcutrecht.nl
authors.forename: Walter M
authors.initials: WM
authors.lastname: van den Bergh
authors.forename: Richard S C
authors.initials: RS
authors.lastname: Kerr
authors.forename: Ale
authors.initials: A
authors.lastname: Algra
authors.forename: Gabriel J E
authors.initials: GJ
authors.lastname: Rinkel
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Molyneux
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D003625:Data Collection; D005260:Female; D006801:Humans; D007431:Intraoperative Complications / Q000097:blood / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012306:Risk; D015607:Stents; D013345:Subarachnoid Hemorrhage / Q000097:blood* / Q000601:surgery*; D013525:Surgical Instruments; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin